We can study ultrarare tumors effectively in this day and age, it just takes a cooperative approach: The role of dasatinib in assorted indolent sarcomas.
Where this comes from
- Record sourced from PubMed, PMID 27696384.
- Also identified by DOI 10.1002/cncr.30377 and PMC identifier 5215314.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Dasatinib may be an active agent in assorted indolent sarcomas. The impact of endpoint selection, well‐defined cohorts, and responses (Choi criteria vs Response Evaluation Criteria in Solid Tumors) are discussed. See also pages 90‐7.
Medical subject headings
- Dasatinib
- Sarcoma